StudyID,Drug_Name,Arm_ID,Date_End,Results_Posted_Or_Updated_Date,Study_Status,Outcome,Termination,No_Amendment,No_Substan_Amend,No_Sub_Screen,No_Sub_Enroll,Screen_Failure,Reasons_Screen_Fail,Enroll_Rate,Time_FPI,Prop_Center_Enroll_Target,Completer,Withdrawer,Discont_AE,Discont_LE,Loss_FU,Protocol_Viol,Treat_Adherence,Visit_Adherence,Assess_Adherence,Med_Treat,Med_Follow_Up,Discont,Med_Discont,Missing_All,Missing_PE,Missing_Key_SE,Med_Age,Min_Age,Max_Age,Prop_NA,Prop_AP,Prop_EU,Prop_AF,Prop_White,Prop_Asian,Prop_Black,Prop_Male,Heter_Index,Prop_Renal,Prop_Hepatic,Prop_HighRisk,Line0,Line1,Line2,Line3,Lapsed,Refractory,Prop_ECOG0,Prop_ECOG1,Prop_ECOG2,Prop_ECOG3,TEAEs,TRAEs,SAEs,Grade34_TEAEs,Grade34_TRAEs,AE_Spec,Inc_TEAES,Inc_Grade34_TEAEs,Grade34_Lab,Death_rate,No_Dosage,Dosage_Level,Dosing_Frequency,Cycle_Length,Formulation,group_id_raw,group_title_raw,group_desc_raw,N_group,count_male,count_female,count_white,count_black,count_asian,count_other,Missing_K
NCT01673867,,NCT01673867_P1,"December 17, 2021","February 26, 2016",Completed,,,,,,292,,,,,,,,,,,,,,,,,,,,,,60.9,18,,,,,,0.9144,0.0308,0.024,0.5171,0.1614,,,,,,,,,,,,,,,,,,,,,,,,,,,,,B1,Nivolumab,"Nivolumab 3 mg/kg solution administered intravenously every 2 weeks. Eligible participants transitioned to nivolumab 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.",292,151,141,267,7,9,9,5
NCT01673867,,NCT01673867_P2,"December 17, 2021","February 26, 2016",Completed,,,,,,290,,,,,,,,,,,,,,,,,,,,,,62.3,18,,,,,,0.9172,0.0276,0.031,0.5793,0.1564,,,,,,,,,,,,,,,,,,,,,,,,,,,,,B2,Docetaxel,"Docetaxel 75mg/m^2 solution administered intravenously every 3 weeks. Eligible participants transitioned to nivolumab 3 mg/kg every 2 weeks or 480 mg every 4 weeks. Participants treated until disease progression, discontinuation due to toxicity, withdrawal of consent or end of study.",290,168,122,266,9,8,7,5
NCT01673867,,NCT01673867_B3,"December 17, 2021","February 26, 2016",Completed,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,B3,Total,Total of all reporting groups,,,,,,,,11
